☰

Melissa Millard, Ph.D. - Publications

Affiliations: 
2013 Pharmaceutical Sciences University of Southern California, Los Angeles, CA, United States 
Area:
Pharmacy, Pharmacology, Oncology
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Guo Q, Millard M, Wilhelm C, Elrod A, Erdman N, Dobrolecki LE, McKinley B, Rippon M, Cornett W, Rinkliff J, Scopteuolo A, Gray L, Epling J, Garner B, Hanna J, et al. Abstract 5673: Complex, patient-derived, multi-cell type, 3D models of breast cancer for personalized prediction of therapeutic response Cancer Research. 78: 5673-5673. DOI: 10.1158/1538-7445.Am2018-5673  0.423
2018 Smith AM, Millard M, Holmes L, Lewis MT, Dobrolecki LE, Kanos C, Gardner S, Hodge P, Nelson F, Lynn M, Edenfield J, Corless C, Schammel D, Crosswell HE, DesRochers TM. Abstract 1121: Profiling patient-specific glioblastoma drug response in vitro using complex 3D microtumors Cancer Research. 78: 1121-1121. DOI: 10.1158/1538-7445.Am2018-1121  0.373
2017 Millard M, Lotstein A, Holmes L, Schammel D, Chung K, Edenfield J, Crosswell HE, DesRochers T. Abstract 1923: Paired isolation and expansion of CSC and CTC from primary small cell lung cancer patient tissue and blood using the 3DKUBE bioreactor platform Cancer Research. 77: 1923-1923. DOI: 10.1158/1538-7445.Am2017-1923  0.459
2016 DesRochers TM, Millard M, Lotstein A, Holmes L, Crosswell HE. Abstract 2531: Marker free isolation and expansion of cancer stem cells from small cell lung cancer Cancer Research. 76: 2531-2531. DOI: 10.1158/1538-7445.Am2016-2531  0.479
2013 Millard M, Gallagher JD, Olenyuk BZ, Neamati N. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. Journal of Medicinal Chemistry. 56: 9170-9. PMID 24147900 DOI: 10.1021/Jm4012438  0.673
2013 Ji Y, Majumder S, Millard M, Borra R, Bi T, Elnagar AY, Neamati N, Shekhtman A, Camarero JA. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. Journal of the American Chemical Society. 135: 11623-33. PMID 23848581 DOI: 10.1021/Ja405108P  0.597
2013 Shabaik YH, Millard M, Neamati N. Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells. Plos One. 8: e54346. PMID 23349858 DOI: 10.1371/Journal.Pone.0054346  0.719
2013 Millard M, Neamati N. Abstract 2480: Discovery and mechanistic characterization of AV220, a novel small molecule targeting cancer cell metabolism. Cancer Research. 73: 2480-2480. DOI: 10.1158/1538-7445.Am2013-2480  0.611
2011 Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 1: 154-88. PMID 21547158 DOI: 10.7150/Thno/V01P0154  0.566
2011 Yamada R, Cao X, Butkevich AN, Millard M, Odde S, Mordwinkin N, Gundla R, Zandi E, Louie SG, Petasis NA, Neamati N. Discovery and preclinical evaluation of a novel class of cytotoxic propynoic acid carbamoyl methyl amides (PACMAs). Journal of Medicinal Chemistry. 54: 2902-14. PMID 21443194 DOI: 10.1021/Jm101655D  0.622
2011 Millard M, Pathania D, Grande F, Xu S, Neamati N. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Current Pharmaceutical Design. 17: 536-59. PMID 21391905 DOI: 10.2174/138161211795222649  0.687
2011 Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, Neamati N. Abstract 2542: Preclinical studies of novel phosphonium salts with broad-spectrum activity Cancer Research. 71: 2542-2542. DOI: 10.1158/1538-7445.Am2011-2542  0.692
2010 Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, Neamati N. Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. Plos One. 5. PMID 20957228 DOI: 10.1371/Journal.Pone.0013131  0.67
2010 Xu J, Millard M, Ren X, Cox OT, Erdreich-Epstein A. c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. Blood. 115: 2709-18. PMID 20124512 DOI: 10.1182/Blood-2009-05-223776  0.329
2009 Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Advanced Drug Delivery Reviews. 61: 1250-75. PMID 19716393 DOI: 10.1016/J.Addr.2009.05.010  0.764
2005 Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, Shimada H, Millard M. Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood. 105: 4353-61. PMID 15705795 DOI: 10.1182/Blood-2004-08-3098  0.346
2002 Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. The Journal of Biological Chemistry. 277: 49531-7. PMID 12388538 DOI: 10.1074/Jbc.M209962200  0.352
Show low-probability matches.